UK medicines regulator approves Wegovy weight-loss pill, available privately before potential NHS review

Unbiased summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy semaglutide tablet for weight loss in the UK, making it the third country globally and first in Europe to do so. The once-daily pill is approved for adults with a BMI of 30 or above, or those with a BMI of 27-30 with a weight-related health condition. Clinical trials showed average weight loss of 14-17% after 64 weeks at the highest dose. The drug will be available via private prescription within weeks through pharmacies and clinics, but will not be available on the NHS until the National Institute for Health and Care Excellence (NICE) conducts its assessment. NICE confirmed Novo Nordisk has not yet made a formal submission. UK pricing has not been confirmed. The pill offers a refrigeration-free alternative to the existing weekly injection.

Coverage by outlet

The Guardian left

Angle Informative and policy-focused, emphasising access barriers and cost concerns for patients.

Bias The Guardian gives thorough factual detail including dosing instructions and side effect mention, and helpfully contextualises the NHS access gap and current private prescription costs for injections. It subtly frames cost as a patient concern ('patients will hope they are cheaper') without sensationalising, which is broadly neutral but carries a mild consumer-advocacy tone. It omits the specific retail pharmacy names planning to stock the pill and does not mention the US price comparator, leaving the cost picture slightly less complete than other outlets.

Wegovy weight-loss pills to be available for patients in UK to buy

BBC News centre-left

Angle Consumer-convenience framing, highlighting practical benefits of the pill format over injections.

Bias The BBC leads with practical consumer benefits — no fridge storage, once-daily convenience — which, while factually accurate, subtly favours a positive product framing. It usefully adds that NICE confirmed no formal submission from Novo Nordisk yet and mentions competitor drugs in development, providing broader market context absent elsewhere. The US price reference of $149/month is included as an indicative figure without clarifying it is the lowest starting dose, which could understate likely costs for most patients.

Weight-loss drug Wegovy to be available in pill form in UK for first time

The Independent centre-left

Angle Straightforward regulatory announcement framing, led by the clinical and eligibility detail.

Bias The Independent offers one of the more clinically precise accounts, correctly distinguishing between the 14% average weight loss across all trial participants and the 17% figure for those who remained on treatment — a nuance some outlets conflate or omit. It includes a direct quote from the MHRA's own executive, lending institutional credibility. It does not mention retail pharmacy names, US pricing, or the NHS cost negotiation context reported by other outlets, making its coverage narrower in scope but also less prone to speculation.

First daily pill for weight loss approved by medicines regulator

Daily Mail right

Angle Celebratory and commercially enthusiastic, self-promoting an exclusive scoop while emphasising consumer access and cost savings.

Bias The Daily Mail twice references its own prior 'exclusive' reporting, introducing a self-promotional tone absent from other outlets, and uses hyperbolic language such as 'blockbuster' and 'game-changing treatment.' It claims the pill 'will be cheaper than injections' in the headline as established fact, whereas pricing has not been officially confirmed — this is speculative based on US comparisons. It uniquely names specific retailers (Morrisons, Boots, Superdrug) and frames the NHS delay negatively by attributing a 'claims' qualifier to NICE's statement, subtly casting doubt on the regulator's account.

Wegovy Pill weight-loss drug approved for use in Britain - and it will be cheaper than injections